




Merrimack  
Investor Relations Department  
One Kendall Square  
Suite B7201  
Cambridge, MA 02139  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: MACK

|               |  |
|---------------|--|
| Last Trade:   | 1.35   |
| Trade Time:   | 4:00 PM ET<br>Jun 23, 2017   |
| Change:       | -0.11  (-7.534%) |
| Day Range     | 1.33 - 1.50  |
| 52-Week Range | 1.13 - 6.79  |
| Volume        | 4,364,691  |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of our product candidates, including three in clinical studies and several others in preclinical development, fit into our three-pronged strategy of 1) understanding the biological problems we are trying to solve, 2) designing specific solution... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 19, 2017*

[Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018](#)

*Jun 8, 2017*

[Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources](#)

*May 25, 2017*

[Merrimack Announces Management Change](#)

*May 10, 2017*

[Merrimack Reports First Quarter 2017 Financial Results](#)

*May 2, 2017*

[Merrimack Announces Timing of First Quarter 2017 Investor Conference Call](#)

## Financials [\[ View all \]](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)